圣泉集团(605589.SH)：拟429万美元收购尚博医药13.50%股权

Core Viewpoint - Shengquan Group (605589.SH) aims to enhance its competitiveness and operational efficiency by optimizing the governance structure of its subsidiary, Shangbo Pharmaceutical, through a share acquisition agreement with Baooushinte [1] Group 1: Share Acquisition - The company plans to acquire a 13.50% stake in its subsidiary, Shangbo Pharmaceutical, from Baooushinte using its own funds [1] - The transaction price for the share transfer is set at $4.29 million [1] Group 2: Strategic Objectives - The acquisition is intended to strengthen the synergy between fine chemicals and pharmaceutical intermediates [1] - The move is part of a broader strategy to improve asset integration efficiency and core competitiveness [1]